Flexion Therapeutics (FLXN) 16.83 $FLXN
Flexion Therapeutics to Present at 2016 Wells Fargo Healthcare Conference
GlobeNewswire - Wed Aug 31, 7:30AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the 11 Annual Wells Fargo Securities Healthcare Conference on Wednesday, September 7, 2016 at 2:55 p.m. EDT at the Westin Boston Waterfront.
FLXN: 16.83 (-0.08), WFC: 50.55 (+0.12)
How Flexion (FLXN) Stock Stands Out in a Strong Industry
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:56AM CDT
Flexion (FLXN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
FLXN: 16.83 (-0.08)
Flexion Therapeutics Reports Second-Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 03, 3:16PM CDT
-- Positive data from completed pivotal Phase 2b and Phase 3 registration trials for Zilretta(TM), Flexion's non-opioid lead drug candidate (also known as FX006), presented at Osteoarthritis Research Society International (OARSI) 2016 World Congress; results demonstrated consistent efficacy across both studies with substantial and durable pain relief
FLXN: 16.83 (-0.08)
Flexion Therapeutics (FLXN) Stock: Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 5:31AM CDT
Flexion Therapeutics Inc (FLXN) may be a solid choice for technical investors, as the firm saw some good news with its moving average crossover.
FLXN: 16.83 (-0.08)
Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Jun 08, 8:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $14.00 per share. The gross proceeds from this offering are expected to be approximately $77.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Flexion. The offering is expected to close on or about June 13, 2016, subject to customary closing conditions. Flexion has also granted the underwriters a 30-day option to purchase up to 825,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
FLXN: 16.83 (-0.08), WFC: 50.55 (+0.12)
Flexion Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Jun 07, 3:05PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell approximately $60.0 million of shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to purchase up to $9.0 million of additional shares of its common stock in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
FLXN: 16.83 (-0.08), WFC: 50.55 (+0.12)
Flexion (FLXN) Zilretta Gets Positive FDA Guidance; Stock Up
Zacks Equity Research - Zacks Investment Research - Fri May 27, 7:12AM CDT
Shares of Flexion (FLXN) rallied after the company received positive guidance from the FDA on the New Drug Application submission for Zilretta.
FLXN: 16.83 (-0.08), ANIP: 59.86 (-1.56), PFE: 34.77 (+0.09), BMY: 56.35 (-0.41)
Flexion Therapeutics Receives Positive Guidance from FDA on New Drug Application (NDA) Submission for Zilretta(TM) for Osteoarthritis of the Knee
GlobeNewswire - Thu May 26, 6:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announces that yesterday it received written responses from the U.S. Food & Drug Administration (FDA) to questions the company had submitted in advance of a pre-NDA meeting regarding Flexion's lead product candidate, Zilretta (also known as FX006). The FDA clearly indicates in its responses that the safety and efficacy data from the registration program for Zilretta are "acceptable to support filing of an NDA submission." Based on this positive FDA feedback, the in-person pre-NDA meeting has become unnecessary and the FDA responses will serve as the official meeting minutes.
FLXN: 16.83 (-0.08)
Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors
GlobeNewswire - Fri May 20, 5:00AM CDT
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company"
(NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system ("CNS" pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease ("PD" , today announced the appointment of Frederick W. Driscoll to its board of directors, effective May 20, 2016. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies. Mr. Driscoll will also serve on Cynapsus' audit committee.
OXGN: 0.70 (-0.03), FLXN: 16.83 (-0.08), CYNA: 39.68 (-0.02), CTH.TO: 51.58 (-0.40)
Flexion Therapeutics Reports First-Quarter 2016 Financial Results
GlobeNewswire - Thu May 12, 3:01PM CDT
-- Zilretta(TM), Flexion's non-opioid lead drug candidate (also known as FX006), completed pivotal Phase 2b and Phase 3 clinical registration trials, in patients with osteoarthritis (OA) of the knee
FLXN: 16.83 (-0.08)
Flexion Therapeutics to Report First-Quarter 2016 Financial Results on May 12, 2016
GlobeNewswire - Thu May 05, 7:30AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its first-quarter 2016 financial results on Thursday, May 12, 2016, at 4:30 p.m. ET.
FLXN: 16.83 (-0.08)
Cytel Congratulates Flexion Therapeutics on Release of Phase 3 Data for Zilretta
BusinessWire - Thu May 05, 7:15AM CDT
Cytel Inc., a global provider of clinical research services and software, congratulates its client Flexion Therapeutics, Inc. on the release of Phase 3 data for its lead drug candidate Zilretta (also known as FX006). It was announced in February that the Phase 3 clinical trial met its primary endpoint at week 12, demonstrating highly significant (p<0.0001), durable and clinically meaningful pain relief against placebo in patients with moderate to severe osteoarthritis (OA) knee pain.
FLXN: 16.83 (-0.08)
Flexion Therapeutics Enrolls First Patient in Phase 2 Trial of Zilretta(TM) Among Type 2 Diabetes Patients With Knee Osteoarthritis
GlobeNewswire - Thu Apr 28, 3:06PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported it has enrolled the first patient in a clinical trial to assess the effects of its lead drug candidate, Zilretta (also known as FX006), on blood glucose levels in approximately 36 adults with osteoarthritis (OA) of the knee who also have Type 2 (adult) diabetes.
FLXN: 16.83 (-0.08)
Flexion Therapeutics to Present at 15th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 07, 7:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the 15 Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 3:40 p.m. EDT in New York, NY.
FLXN: 16.83 (-0.08)
Flexion Therapeutics Announces Presentation of Results From Pivotal Phase 2b and Phase 3 Clinical Trials for Zilretta(TM) at Osteoarthritis Research Society International (OARSI) 2016 World Congress
GlobeNewswire - Mon Apr 04, 6:00AM CDT
-- Positive data from Zilretta Phase 2b and Phase 3 clinical trials demonstrate consistent efficacy across both studies with substantial and persistent pain relief
FLXN: 16.83 (-0.08)
Flexion to Present Pivotal Phase 2b and Phase 3 Results for Zilretta(TM) at Osteoarthritis Research Society International (OARSI) 2016 World Congress
GlobeNewswire - Fri Apr 01, 4:07PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report results from the pivotal Phase 2b and Phase 3 clinical trials of its lead drug candidate Zilretta (also known as FX006) at the Osteoarthritis Research Society International (OARSI) 2016 World Congress at the RAI Amsterdam Convention Center in Amsterdam, The Netherlands, on Saturday, April 2 at 2:00 p.m. CET/9:00 a.m. EDT.
FLXN: 16.83 (-0.08)
Holding the Course, Oculus Innovative Sciences Delivers Revenue Growth Again
ACCESSWIRE - Tue Feb 09, 8:25AM CST
REDONDO BEACH, CA / ACCESSWIRE / February 9, 2016 / 2016 has been brutal for many sectors, but perhaps none so much as for biotechnology and pharmaceutical companies. For instance, the Nasdaq Biotechnology Index has been clubbed from 3,550 at the end of December to around 2,550, for a loss of roughly 28 percent. A wider view shows that this sector has been languishing since NBI hit an all-time high of 4,195 in July 2015. Given a $200 million market cap minimum for the index, components are diverse in size, ranging from a giant like Celgene (NASDAQ: CELG) to much smaller companies, such as NeuroDerm (NASDAQ: NDRM) and Flexion Therapeutics (NASDAQ: FLXN), demonstrating how broad the sell-off has been.
FLXN: 16.83 (-0.08), OCLS: 4.14 (+0.01), NDRM: 16.08 (-0.18), CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Is Flexion Therapeutics (FLXN) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:02AM CST
Flexion Therapeutics is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective
FLXN: 16.83 (-0.08)
Osteoarthritis Pain Therapeutics Pipeline Review, H2 2015 - 29 Companies & 50 Drug Profiles
M2 - Thu Dec 17, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/v8nbgw/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Allergan Plc - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bone Medical Limited - Centrexion Corporation - Convergence Pharmaceuticals Ltd. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Flexion Therapeutics, Inc. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA Drug Profiles - (lidocaine hydrochloride tetracaine hydrochloride) - (naltrexone hydrochloride oxycodone hydrochloride) SR - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - capsaicin - cebranopadol - celecoxib - CGS-125 - CR-4056 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - MEDI-7352 - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A For more information visit http://www.researchandmarkets.com/research/v8...oarthritis
FLXN: 16.83 (-0.08), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), AMPE: 0.85 (-0.01), LLY: 76.85 (-0.38), NKTR: 18.45 (+0.34), AGN: 235.96 (-1.80), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), POZN: 5.94 (-0.43), REGN: 388.64 (-4.76), PTIE: 2.27 (-0.05)
Flexion Therapeutics, Inc. Market - Global Product Pipeline Review - 2015
M2 - Tue Dec 15, 3:48AM CST
Summary
FLXN: 16.83 (-0.08)
Flexion Therapeutics to Present at 2016 Wells Fargo Healthcare Conference
GlobeNewswire - Wed Aug 31, 7:30AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the 11 Annual Wells Fargo Securities Healthcare Conference on Wednesday, September 7, 2016 at 2:55 p.m. EDT at the Westin Boston Waterfront.
FLXN: 16.83 (-0.08), WFC: 50.55 (+0.12)
How Flexion (FLXN) Stock Stands Out in a Strong Industry
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:56AM CDT
Flexion (FLXN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
FLXN: 16.83 (-0.08)
Flexion Therapeutics Reports Second-Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 03, 3:16PM CDT
-- Positive data from completed pivotal Phase 2b and Phase 3 registration trials for Zilretta(TM), Flexion's non-opioid lead drug candidate (also known as FX006), presented at Osteoarthritis Research Society International (OARSI) 2016 World Congress; results demonstrated consistent efficacy across both studies with substantial and durable pain relief
FLXN: 16.83 (-0.08)
Flexion Therapeutics (FLXN) Stock: Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 5:31AM CDT
Flexion Therapeutics Inc (FLXN) may be a solid choice for technical investors, as the firm saw some good news with its moving average crossover.
FLXN: 16.83 (-0.08)
Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Jun 08, 8:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $14.00 per share. The gross proceeds from this offering are expected to be approximately $77.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Flexion. The offering is expected to close on or about June 13, 2016, subject to customary closing conditions. Flexion has also granted the underwriters a 30-day option to purchase up to 825,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
FLXN: 16.83 (-0.08), WFC: 50.55 (+0.12)
Flexion Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Jun 07, 3:05PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell approximately $60.0 million of shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to purchase up to $9.0 million of additional shares of its common stock in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
FLXN: 16.83 (-0.08), WFC: 50.55 (+0.12)
Flexion (FLXN) Zilretta Gets Positive FDA Guidance; Stock Up
Zacks Equity Research - Zacks Investment Research - Fri May 27, 7:12AM CDT
Shares of Flexion (FLXN) rallied after the company received positive guidance from the FDA on the New Drug Application submission for Zilretta.
FLXN: 16.83 (-0.08), ANIP: 59.86 (-1.56), PFE: 34.77 (+0.09), BMY: 56.35 (-0.41)
Flexion Therapeutics Receives Positive Guidance from FDA on New Drug Application (NDA) Submission for Zilretta(TM) for Osteoarthritis of the Knee
GlobeNewswire - Thu May 26, 6:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announces that yesterday it received written responses from the U.S. Food & Drug Administration (FDA) to questions the company had submitted in advance of a pre-NDA meeting regarding Flexion's lead product candidate, Zilretta (also known as FX006). The FDA clearly indicates in its responses that the safety and efficacy data from the registration program for Zilretta are "acceptable to support filing of an NDA submission." Based on this positive FDA feedback, the in-person pre-NDA meeting has become unnecessary and the FDA responses will serve as the official meeting minutes.
FLXN: 16.83 (-0.08)
Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors
GlobeNewswire - Fri May 20, 5:00AM CDT
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company"
(NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system ("CNS" pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease ("PD" , today announced the appointment of Frederick W. Driscoll to its board of directors, effective May 20, 2016. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies. Mr. Driscoll will also serve on Cynapsus' audit committee. OXGN: 0.70 (-0.03), FLXN: 16.83 (-0.08), CYNA: 39.68 (-0.02), CTH.TO: 51.58 (-0.40)
Flexion Therapeutics Reports First-Quarter 2016 Financial Results
GlobeNewswire - Thu May 12, 3:01PM CDT
-- Zilretta(TM), Flexion's non-opioid lead drug candidate (also known as FX006), completed pivotal Phase 2b and Phase 3 clinical registration trials, in patients with osteoarthritis (OA) of the knee
FLXN: 16.83 (-0.08)
Flexion Therapeutics to Report First-Quarter 2016 Financial Results on May 12, 2016
GlobeNewswire - Thu May 05, 7:30AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its first-quarter 2016 financial results on Thursday, May 12, 2016, at 4:30 p.m. ET.
FLXN: 16.83 (-0.08)
Cytel Congratulates Flexion Therapeutics on Release of Phase 3 Data for Zilretta
BusinessWire - Thu May 05, 7:15AM CDT
Cytel Inc., a global provider of clinical research services and software, congratulates its client Flexion Therapeutics, Inc. on the release of Phase 3 data for its lead drug candidate Zilretta (also known as FX006). It was announced in February that the Phase 3 clinical trial met its primary endpoint at week 12, demonstrating highly significant (p<0.0001), durable and clinically meaningful pain relief against placebo in patients with moderate to severe osteoarthritis (OA) knee pain.
FLXN: 16.83 (-0.08)
Flexion Therapeutics Enrolls First Patient in Phase 2 Trial of Zilretta(TM) Among Type 2 Diabetes Patients With Knee Osteoarthritis
GlobeNewswire - Thu Apr 28, 3:06PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported it has enrolled the first patient in a clinical trial to assess the effects of its lead drug candidate, Zilretta (also known as FX006), on blood glucose levels in approximately 36 adults with osteoarthritis (OA) of the knee who also have Type 2 (adult) diabetes.
FLXN: 16.83 (-0.08)
Flexion Therapeutics to Present at 15th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 07, 7:00AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the 15 Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 3:40 p.m. EDT in New York, NY.
FLXN: 16.83 (-0.08)
Flexion Therapeutics Announces Presentation of Results From Pivotal Phase 2b and Phase 3 Clinical Trials for Zilretta(TM) at Osteoarthritis Research Society International (OARSI) 2016 World Congress
GlobeNewswire - Mon Apr 04, 6:00AM CDT
-- Positive data from Zilretta Phase 2b and Phase 3 clinical trials demonstrate consistent efficacy across both studies with substantial and persistent pain relief
FLXN: 16.83 (-0.08)
Flexion to Present Pivotal Phase 2b and Phase 3 Results for Zilretta(TM) at Osteoarthritis Research Society International (OARSI) 2016 World Congress
GlobeNewswire - Fri Apr 01, 4:07PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report results from the pivotal Phase 2b and Phase 3 clinical trials of its lead drug candidate Zilretta (also known as FX006) at the Osteoarthritis Research Society International (OARSI) 2016 World Congress at the RAI Amsterdam Convention Center in Amsterdam, The Netherlands, on Saturday, April 2 at 2:00 p.m. CET/9:00 a.m. EDT.
FLXN: 16.83 (-0.08)
Holding the Course, Oculus Innovative Sciences Delivers Revenue Growth Again
ACCESSWIRE - Tue Feb 09, 8:25AM CST
REDONDO BEACH, CA / ACCESSWIRE / February 9, 2016 / 2016 has been brutal for many sectors, but perhaps none so much as for biotechnology and pharmaceutical companies. For instance, the Nasdaq Biotechnology Index has been clubbed from 3,550 at the end of December to around 2,550, for a loss of roughly 28 percent. A wider view shows that this sector has been languishing since NBI hit an all-time high of 4,195 in July 2015. Given a $200 million market cap minimum for the index, components are diverse in size, ranging from a giant like Celgene (NASDAQ: CELG) to much smaller companies, such as NeuroDerm (NASDAQ: NDRM) and Flexion Therapeutics (NASDAQ: FLXN), demonstrating how broad the sell-off has been.
FLXN: 16.83 (-0.08), OCLS: 4.14 (+0.01), NDRM: 16.08 (-0.18), CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Is Flexion Therapeutics (FLXN) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:02AM CST
Flexion Therapeutics is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective
FLXN: 16.83 (-0.08)
Osteoarthritis Pain Therapeutics Pipeline Review, H2 2015 - 29 Companies & 50 Drug Profiles
M2 - Thu Dec 17, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/v8nbgw/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Allergan Plc - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bone Medical Limited - Centrexion Corporation - Convergence Pharmaceuticals Ltd. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Flexion Therapeutics, Inc. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA Drug Profiles - (lidocaine hydrochloride tetracaine hydrochloride) - (naltrexone hydrochloride oxycodone hydrochloride) SR - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - capsaicin - cebranopadol - celecoxib - CGS-125 - CR-4056 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - MEDI-7352 - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A For more information visit http://www.researchandmarkets.com/research/v8...oarthritis
FLXN: 16.83 (-0.08), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), AMPE: 0.85 (-0.01), LLY: 76.85 (-0.38), NKTR: 18.45 (+0.34), AGN: 235.96 (-1.80), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), POZN: 5.94 (-0.43), REGN: 388.64 (-4.76), PTIE: 2.27 (-0.05)
Flexion Therapeutics, Inc. Market - Global Product Pipeline Review - 2015
M2 - Tue Dec 15, 3:48AM CST
Summary
FLXN: 16.83 (-0.08)
